Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Bolognese

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Statistics in Medicine|February 5, 2008
Adaptive dose finding based on t-statistic for dose-response trialsAnastasia Ivanova, James A Bolognese, Inna Perevozskaya
Therapeutic Innovation & Regulatory Science|September 19, 2018
Evaluation of an Adaptive Maximizing Design Study Based on Clinical Utility Versus Morphine for TRV130 Proof-of-Concept and Dose-Regimen Finding in Patients With Postoperative Pain After BunionectomyJames A Bolognese, Ruth Ann Subach, Franck Skobieranda
Arthritis and Rheumatism|November 13, 2003
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation studyJennifer J Anderson, James A Bolognese, David T Felson
The AAPS Journal|September 19, 2009
Evaluation of agile designs in first-in-human (FIH) trials--a simulation studyItay Perlstein, James A Bolognese, Rajesh Krishna, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Current Medical Research and Opinion|May 23, 2002
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agentsBarry J Gertz, David Krupa, James A Bolognese, et al.
Current Medical Research and Opinion|October 7, 2004
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisDouglas J Watson, Qinfen Yu, James A Bolognese, et al.
Current Medical Research and Opinion|February 3, 2007
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxibSean P Curtis, Amy T Ko, James A Bolognese, et al.
Current Medical Research and Opinion|June 25, 2005
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysisDena R Ramey, Douglas J Watson, Chang Yu, et al.
Pain Medicine (Malden, Mass.)|July 5, 2012
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scaleArnold R Gammaitoni, Steven S Smugar, Mark P Jensen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Statistics in Medicine|February 5, 2008
Adaptive dose finding based on t-statistic for dose-response trialsAnastasia Ivanova, James A Bolognese, Inna Perevozskaya
Therapeutic Innovation & Regulatory Science|September 19, 2018
Evaluation of an Adaptive Maximizing Design Study Based on Clinical Utility Versus Morphine for TRV130 Proof-of-Concept and Dose-Regimen Finding in Patients With Postoperative Pain After BunionectomyJames A Bolognese, Ruth Ann Subach, Franck Skobieranda
Arthritis and Rheumatism|November 13, 2003
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation studyJennifer J Anderson, James A Bolognese, David T Felson
The AAPS Journal|September 19, 2009
Evaluation of agile designs in first-in-human (FIH) trials--a simulation studyItay Perlstein, James A Bolognese, Rajesh Krishna, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Current Medical Research and Opinion|May 23, 2002
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agentsBarry J Gertz, David Krupa, James A Bolognese, et al.
Current Medical Research and Opinion|October 7, 2004
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisDouglas J Watson, Qinfen Yu, James A Bolognese, et al.
Current Medical Research and Opinion|February 3, 2007
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxibSean P Curtis, Amy T Ko, James A Bolognese, et al.
Current Medical Research and Opinion|June 25, 2005
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysisDena R Ramey, Douglas J Watson, Chang Yu, et al.
Pain Medicine (Malden, Mass.)|July 5, 2012
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scaleArnold R Gammaitoni, Steven S Smugar, Mark P Jensen, et al.
Pageof 3